These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22362862)

  • 1. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia.
    Floyd K; Hutubessy R; Kliiman K; Centis R; Khurieva N; Jakobowiak W; Danilovits M; Peremitin G; Keshavjee S; Migliori GB
    Eur Respir J; 2012 Jul; 40(1):133-42. PubMed ID: 22362862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
    BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.
    Fitzpatrick C; Floyd K
    Pharmacoeconomics; 2012 Jan; 30(1):63-80. PubMed ID: 22070215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of multi drug resistance tuberculosis in Germany.
    Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
    Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia.
    Alemayehu S; Yigezu A; Hailemariam D; Hailu A
    PLoS One; 2020; 15(7):e0235820. PubMed ID: 32716915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of the russian treatment scheme for tuberculosis versus short-course chemotherapy: results from Tomsk, Siberia.
    Jacobs B; Clowes C; Wares F; Polivakho V; Lyagoshina T; Peremitin G; Banatvala N
    Int J Tuberc Lung Dis; 2002 May; 6(5):396-405. PubMed ID: 12019915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
    Laurence YV; Griffiths UK; Vassall A
    Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
    Schnippel K; Rosen S; Shearer K; Martinson N; Long L; Sanne I; Variava E
    Trop Med Int Health; 2013 Jan; 18(1):109-16. PubMed ID: 23170876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of treatment for multidrug-resistant tuberculosis in South Korea.
    Kang YA; Choi YJ; Cho YJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
    Respirology; 2006 Nov; 11(6):793-8. PubMed ID: 17052310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia.
    Shin SS; Pasechnikov AD; Gelmanova IY; Peremitin GG; Strelis AK; Mishustin S; Barnashov A; Karpeichik Y; Andreev YG; Golubchikova VT; Tonkel TP; Yanova GV; Nikiforov M; Yedilbayev A; Mukherjee JS; Furin JJ; Barry DJ; Farmer PE; Rich ML; Keshavjee S
    Int J Tuberc Lung Dis; 2006 Apr; 10(4):402-8. PubMed ID: 16602404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
    Nathanson E; Gupta R; Huamani P; Leimane V; Pasechnikov AD; Tupasi TE; Vink K; Jaramillo E; Espinal MA
    Int J Tuberc Lung Dis; 2004 Nov; 8(11):1382-4. PubMed ID: 15581210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
    Diel R; Hittel N; Schaberg T
    Respir Med; 2015 May; 109(5):632-41. PubMed ID: 25862597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis: cost of illness in Germany.
    Diel R; Rutz S; Castell S; Schaberg T
    Eur Respir J; 2012 Jul; 40(1):143-51. PubMed ID: 22267754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 18. Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador.
    Rouzier VA; Oxlade O; Verduga R; Gresely L; Menzies D
    Int J Tuberc Lung Dis; 2010 Oct; 14(10):1316-22. PubMed ID: 20843424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru.
    Suárez PG; Floyd K; Portocarrero J; Alarcón E; Rapiti E; Ramos G; Bonilla C; Sabogal I; Aranda I; Dye C; Raviglione M; Espinal MA
    Lancet; 2002 Jun; 359(9322):1980-9. PubMed ID: 12076553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.